Login / Signup

Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis.

Joseph JacobBrian J BartholmaiSrinivasan RajagopalanColine H M van MoorselHendrik W van EsFrouke T van BeekMarjolijn H L StruikMaria KokosiRyoko EgashiraAnne Laure BrunArjun NairSimon L F WalshGary CrossJoseph BarnettAngelo de LauretisEoin P JudgeSujal DesaiRonald KarwoskiSebastien OurselinElisabetta RenzoniToby M MaherAndre AltmannAthol U Wells
Published in: American journal of respiratory and critical care medicine (2019)
Our study has validated a new quantitative CT measure in patients with IPF fulfilling drug trial entry criteria-the VRS score-that outperformed current gold standard measures of outcome. When used for cohort enrichment in an IPF drug trial setting, VRS threshold scores can reduce a required IPF drug trial population size by 25%, thereby limiting prohibitive trial costs. Importantly, VRS scores identify patients in whom antifibrotic medication prolongs life and reduces FVC decline.
Keyphrases